Diabetes

News

Novo Nordisk has been handed a crucial legal win by China's Supreme Court, which backed the validity of its patent on GLP-1 agonist semaglutide.

Patients

Simplifying the complexity of medical treatments extends beyond convenience to improving equity.

News

CMS has revealed a new, voluntary access programme that aims to broaden the use of GLP-1 agonist medicines for diabetes and obesity.

News

A real-world study exploring the long-term effects of Eli Lilly's weight-loss therapy tirzepatide in primary care settings has started in the UK.

News

Novo Nordisk has decided to move its amycretin into pivotal trials in type 2 diabetes after a phase 2 readout.

News

Eli Lilly has become the first pharma group to reach a value of more than $1 trillion, joining a select group populated mainly by tech giants.